Global Market For Cardiotonic Agents Market Report 2025 – Insights For Firms Seeking Growth & Competitive Advantage

Cardiotonic Agents Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

The Business Research Company’s Cardiotonic Agents Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, June 16, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

What Does The Data On The Cardiotonic Agents Market Size Indicate?
Growth has been prolific in the cardiotonic agents market in recent years, expanding from $2.78 billion in 2024 to an impressive $3.14 billion in 2025. This growth trajectory signifies a compound annual growth rate CAGR of 12.9%. What were the main drivers of this historic growth? Justifications include an increasing prevalence of heart failure, a rising geriatric population, growing incidences of coronary artery disease, the adoption of sedentary lifestyles, and burdens stemming from hypertension and diabetes.

What Is The Anticipated Growth Of The Cardiotonic Agents Market?
Projections suggest the market size of cardiotonic agents will see further climbs in the coming years, increasing to $5.06 billion in 2029, with a CAGR of 12.6%. Causes for this predicted expansion in the forecast period are likely to be tied to rising cardiovascular mortality rates, an escalation in clinical trials focusing on enhanced cardiotonic formulations, increasing public-private partnerships in cardiovascular drug development, and a growing demand for personalized cardiovascular medicine.

The cardiotonic agents market report also highlights crucial trends expected to make significant contributions during the forecast period. These advancements include the development of peptide-based cardiotonic agents, dual-mechanism drug development, the incorporation of pharmacogenomics, the innovation of injectable depot formulations, and combination therapies.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

What Is Driving The Growth In The Cardiotonic Agents Market?
The cardiotonic agents market performance is significantly influenced by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases CVDs, including conditions such as coronary artery disease, heart failure, arrhythmias, and stroke, affect the heart and blood vessels. The growth in these diseases can be largely attributed to diets high in saturated fats, trans fats, salt, and added sugars, leading to obesity, high blood pressure, and elevated cholesterol levels. To combat these health issues, cardiotonic agents are administered to improve heart efficiency and contraction strength, aiding blood circulation and reducing symptoms related to various cardiovascular diseases.

For instance, reports from the Australian Institute of Health and Welfare revealed that doctor-certified deaths due to coronary heart disease CHD in Australia increased from 14,100 in 2021 to 14,900 in 2022. Therefore, the escalating prevalence of cardiovascular

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

Who Are The Keen Competitors In The Cardiotonic Agents Market
The factors as delineated will inevitably attract a flurry of key industry players. Major participants include titans such as Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, and Fresenius Kabi. Other noteworthy competitors in the market include Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, and Deccan Nutraceuticals Pvt. Ltd.

What Are The Emerging Trends In The Cardiotonic Agents Market?
These companies are adapting to the ever-evolving the cardiotonic agents market with the development of innovative products such as short-term inotropic drugs intended to enhance cardiac performance in acute heart failure and cardiogenic shock. For instance, in June 2023, UK-based pharmaceutical company Hikma Pharmaceuticals plc introduced Dobutamine Injection, USP in a 250 mg/20 ml vial. This injection, used for short-term inotropic support in adults experiencing cardiac decompensation due to reduced heart contractility, works by stimulating beta-1 receptors, thereby improving heart muscle contractility and cardiac output.

How Is The Cardiotonic Agents Market Segmented?

The cardiotonic agents market report provides an in-depth overview of the segmentation:
1 By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types
2 By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3 By Dosage Form: Tablet, Solution, Other Dosage Forms
4 By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications
5 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Sub-segments include By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C; By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone; By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine; By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine; By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol.

What Regional Insights Impact The Cardiotonic Agents Market Logistics?
Regional insights reveal that the largest territory for the cardiotonic agents market in 2024 was North America, with Asia-Pacific anticipated to be the fastest-growing region in future forecasts. The regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Pediatric Interventional Cardiology Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-interventional-cardiology-global-market-report

Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hypertrophic-cardiomyopathy-hcm-therapeutics-global-market-report

Cardiovascular Digital Solutions Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiovascular-digital-solutions-global-market-report

The Business Research Company publish equipped with over 15000+ reports across 27 industries and 60+ global locations. With an optimistic repertoire consisting of over 1,500,000 datasets, in-depth secondary research, and distinctive insights from industry leaders, The Business Research Company provides essential information to maintain a competitive edge in the industry.

For further details, contact:
The Business Research Company: Contact ushttps://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Get the latest updates from:
LinkedIn: Follow ushttps://in.linkedin.com/company/the-business-research-company
YouTube: Follow ushttps://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: Follow ushttps://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.